OAR@UM Collection:https://www.um.edu.mt/library/oar/handle/123456789/4312024-03-19T02:54:01Z2024-03-19T02:54:01ZIndications, detection, dompletion and retention rates of capsule endoscopy in two decades of use : a systematic review and meta-analysisCortegoso Valdivia, PabloSkonieczna-Zydecka, KarolinaElosua, AlfonsoSciberras, MartinaPiccirelli, StefaniaRullan, MariaTabone, TrevorGawel, KatarzynaStachowski, AdamLemi ´nski, ArturMarlicz, WojciechFernández-Urién, IgnacioEllul, PierreSpada, CristianoPennazio, MarcoToth, ErvinKoulaouzidis, Anastasioshttps://www.um.edu.mt/library/oar/handle/123456789/1199562024-03-15T16:18:41Z2022-01-01T00:00:00ZTitle: Indications, detection, dompletion and retention rates of capsule endoscopy in two decades of use : a systematic review and meta-analysis
Authors: Cortegoso Valdivia, Pablo; Skonieczna-Zydecka, Karolina; Elosua, Alfonso; Sciberras, Martina; Piccirelli, Stefania; Rullan, Maria; Tabone, Trevor; Gawel, Katarzyna; Stachowski, Adam; Lemi ´nski, Artur; Marlicz, Wojciech; Fernández-Urién, Ignacio; Ellul, Pierre; Spada, Cristiano; Pennazio, Marco; Toth, Ervin; Koulaouzidis, Anastasios
Abstract: Background: Capsule endoscopy (CE) has become a widespread modality for non-invasive
evaluation of the gastrointestinal (GI) tract, with several CE models having been developed throughout the years. The aim of this systematic review and meta-analysis is to evaluate performance
measures such as completion, detection and retention rates of CE. Methods: Literature through to August 2021 was screened for articles regarding all capsule types: small bowel, double-headed capsule
for the colon or PillCam®Crohn’s capsule, magnetically-controlled capsule endoscopy, esophageal
capsule and patency capsule. Primary outcomes included detection rate (DR), completion rate (CR)
and capsule retention rate (RR). DR, CR and RR were also analyzed in relation to indications such as
obscure GI bleeding (OGIB), known/suspected Crohn’s disease (CD), celiac disease (CeD), neoplastic
lesions (NL) and clinical symptoms (CS). Results: 328 original articles involving 86,930 patients who
underwent CE were included. OGIB was the most common indication (n = 44,750), followed by CS
(n = 17,897), CD (n = 11,299), NL (n = 4989) and CeD (n = 947). The most used capsule type was small
bowel CE in 236 studies. DR, CR and RR for all indications were 59%, 89.6% and 2%, respectively.
According to specific indications: DR were 55%, 66%, 63%, 52% and 62%; CR were 90.6%, 86.5%, 78.2%, 94% and 92.8%; and RR were 2%, 4%, 1%, 6% and 2%. Conclusions: Pooled DR, CR and
RR are acceptable for all capsule types. OGIB is the most common indication for CE. Technological
advancements have expanded the scope of CE devices in detecting GI pathology with acceptable
rates for a complete examination.2022-01-01T00:00:00ZEndoscopic postoperative recurrence in Crohn’s disease : after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab : a real-world multicentre European studyYanai, HenitKagramanova, AnnaKnyazev, OlegSabino, JoãoHaenen, ShanaMantzaris, Gerassimos J.Mountaki, KaterinaArmuzzi, AlessandroPugliese, DanielaFurfaro, FedericaFiorino, GionataDrobne, DavidKurent, TinaYassin, SharifMaharshak, NitsanCastiglione, Fabianade Sire, RobertoNardone, Olga MariaFarkas, KlaudiaMolnar, TamasKrznaric, ZeljkoBrinar, MarkoChashkova, ElenaLivne Margolin, MoranKopylov, UriBezzio, CristinaShitrit, AriellaBar-GiLukas, MilanChaparro, MaríaTruyens, MarieNancey, StéphaneLobaton, TrianaGisbert, Javier P.Saibeni, SimoneBacsúr, PéterBossuyt, PeterSchulberg, JulienHoentjen, FrankViganò, ChiaraPalermo, AndreaTorres, JoanaRevés, JoanaKarmiris, KonstantinosVelegraki, MagdaliniSavarino, EdoardoMarkopoulos, PanagiotisTsironi, EftychiaEllul, PierreSuárez, Cristina CalviñoWeisshof, RoniBen-Hur, DanaNaftali, TimnaEriksson, CarlKoutroubakis, Ioannis E.Foteinogiannopoulou, KalliopiLimdi, Jimmy K.Liu, EleanorSurís, GerardCalabrese, EmmaZorzi, FrancescaFilip, RafałRibaldone, Davide GiuseppeSnir, YifatGoren, IdanBanai-Eran, HagarBroytman, YelenaAmir Barak, HadarAvni-Biron, IritOllech, Jacob E.Dotan, IrisGolan, Maya Aharonihttps://www.um.edu.mt/library/oar/handle/123456789/1199552024-03-15T16:04:09Z2022-01-01T00:00:00ZTitle: Endoscopic postoperative recurrence in Crohn’s disease : after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab : a real-world multicentre European study
Authors: Yanai, Henit; Kagramanova, Anna; Knyazev, Oleg; Sabino, João; Haenen, Shana; Mantzaris, Gerassimos J.; Mountaki, Katerina; Armuzzi, Alessandro; Pugliese, Daniela; Furfaro, Federica; Fiorino, Gionata; Drobne, David; Kurent, Tina; Yassin, Sharif; Maharshak, Nitsan; Castiglione, Fabiana; de Sire, Roberto; Nardone, Olga Maria; Farkas, Klaudia; Molnar, Tamas; Krznaric, Zeljko; Brinar, Marko; Chashkova, Elena; Livne Margolin, Moran; Kopylov, Uri; Bezzio, Cristina; Shitrit, AriellaBar-Gi; Lukas, Milan; Chaparro, María; Truyens, Marie; Nancey, Stéphane; Lobaton, Triana; Gisbert, Javier P.; Saibeni, Simone; Bacsúr, Péter; Bossuyt, Peter; Schulberg, Julien; Hoentjen, Frank; Viganò, Chiara; Palermo, Andrea; Torres, Joana; Revés, Joana; Karmiris, Konstantinos; Velegraki, Magdalini; Savarino, Edoardo; Markopoulos, Panagiotis; Tsironi, Eftychia; Ellul, Pierre; Suárez, Cristina Calviño; Weisshof, Roni; Ben-Hur, Dana; Naftali, Timna; Eriksson, Carl; Koutroubakis, Ioannis E.; Foteinogiannopoulou, Kalliopi; Limdi, Jimmy K.; Liu, Eleanor; Surís, Gerard; Calabrese, Emma; Zorzi, Francesca; Filip, Rafał; Ribaldone, Davide Giuseppe; Snir, Yifat; Goren, Idan; Banai-Eran, Hagar; Broytman, Yelena; Amir Barak, Hadar; Avni-Biron, Irit; Ollech, Jacob E.; Dotan, Iris; Golan, Maya Aharoni
Abstract: Background: Endoscopic-post-operative-recurrence [ePOR] in Crohn’s disease [CD] after ileocecal resection [ICR] is a major concern. We aimed
to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab
[VDZ] and ustekinumab [UST] in a real-world setting.
Methods: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a
Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse prob ability treatment weighting [IPTW] was applied to compare the effectiveness between agents.
Results: The study included 297 patients (53.9% males, age at diagnosis 24 years [19–32], age at ICR 34 years [26–43], 18.5% smokers, 27.6%
biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received
anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery.
ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR
at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01–2.97]), past-adalimumab [adj.OR = 2.32
[95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable
(OR = 0.55 [95% CI: 0.25–1.19], OR = 1.86 [95% CI: 0.79–4.38]), respectively.
Conclusion. Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted
of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other
groups.2022-01-01T00:00:00ZECCO guidelines on therapeutics in ulcerative colitis : surgical treatmentSpinelli, AntoninoBonovas, StefanosBurisch, JohanKucharzik, TorstenAdamina, MichelAnnese, VitoBachmann, OliverBettenworth, DominikChaparro, MariaCzuber-Dochan, WladyslawaEder, PiotrEllul, PierreFidalgo, CatarinaFiorino, GionataGionchetti, PaoloGisbert, Javier P.Gordon, HannahHedin, CharlotteHolubar, StefanIacucci, MariettaKarmiris, KonstantinosKatsanos, KonstantinosKopylov, UriLakatos, Peter L.Lytras, TheodoreLyutakov, IvanNoor, NurulaminPellino, GianlucaPiovani, DanieleSavarino, EdoardoSelvaggi, FrancescoVerstockt, BramDoherty, GlenRaine, TimPanisag, Yveshttps://www.um.edu.mt/library/oar/handle/123456789/1199542024-03-15T15:59:49Z2022-01-01T00:00:00ZTitle: ECCO guidelines on therapeutics in ulcerative colitis : surgical treatment
Authors: Spinelli, Antonino; Bonovas, Stefanos; Burisch, Johan; Kucharzik, Torsten; Adamina, Michel; Annese, Vito; Bachmann, Oliver; Bettenworth, Dominik; Chaparro, Maria; Czuber-Dochan, Wladyslawa; Eder, Piotr; Ellul, Pierre; Fidalgo, Catarina; Fiorino, Gionata; Gionchetti, Paolo; Gisbert, Javier P.; Gordon, Hannah; Hedin, Charlotte; Holubar, Stefan; Iacucci, Marietta; Karmiris, Konstantinos; Katsanos, Konstantinos; Kopylov, Uri; Lakatos, Peter L.; Lytras, Theodore; Lyutakov, Ivan; Noor, Nurulamin; Pellino, Gianluca; Piovani, Daniele; Savarino, Edoardo; Selvaggi, Francesco; Verstockt, Bram; Doherty, Glen; Raine, Tim; Panisag, Yves
Abstract: This is the second of a series of two articles reporting the European Crohn’s and Colitis Organisation
[ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis
[UC]. The first article is focused on medical management, and the present article addresses
medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically
refractory UC patients, including preoperative optimisation, surgical strategies, and technical
issues. The article provides advice for a variety of common clinical and surgical conditions.
Together, the articles represent an update of the evidence-based recommendations of the ECCO
for UC.2022-01-01T00:00:00ZECCO topical review : refractory inflammatory bowel diseaseRaine, TimVerstockt, BramKopylov, UriKarmiris, KonstantinosGoldberg, RimmaAtreya, RajaBurisch, JohanBurke, JohnEllul, PierreHedin, CharlotteHolubar, Stefan D.Katsanos, KonstantinosLobaton, TrianaSchmidt, CarstenCullen, Garrethttps://www.um.edu.mt/library/oar/handle/123456789/1199532024-03-15T15:17:55Z2021-01-01T00:00:00ZTitle: ECCO topical review : refractory inflammatory bowel disease
Authors: Raine, Tim; Verstockt, Bram; Kopylov, Uri; Karmiris, Konstantinos; Goldberg, Rimma; Atreya, Raja; Burisch, Johan; Burke, John; Ellul, Pierre; Hedin, Charlotte; Holubar, Stefan D.; Katsanos, Konstantinos; Lobaton, Triana; Schmidt, Carsten; Cullen, Garret
Abstract: Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity, and
activity. A proportion of patients will have disease that is refractory to licensed therapies, resulting
in significant impairment in quality of life. The treatment of these patients involves a systematic
approach by the entire multidisciplinary team, with particular consideration given to medical
options including unlicensed therapies, surgical interventions, and dietetic and psychological
support. The purpose of this review is to guide clinicians through this process and provide an
accurate summary of the available evidence for different strategies.2021-01-01T00:00:00Z